trial

Schizophrenia Treatment Adherence Investigation (STAI)

NCTId NCT01001481
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 550 (actual)
Sponsored by Janssen-Cilag Farmaceutica Ltda.
Primary completion 2009-09
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
550 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2007-07
Primary completion
2009-09
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Risk status for medication adherence

Sponsors

Janssen-Cilag Farmaceutica Ltda.Lead Sponsor

Sites

0 total

Facts & assertions

4 sourced
Enrollment
550
Phase
NA
Primary Completion Date
2009-09
Status
COMPLETED
relationships
The graph out of here
drug
Risk status for medication adherence
drug
lead_sponsor
Janssen-Cilag Farmaceutica Ltda.
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication